Aerovate Therapeutics Inc AVTE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 11/25/22 EST
18.67UNCH (UNCH)
Close
18.67quote price arrow up+0.41 (+2.25%)
Volume
29,798
52 week range
7.74 - 27.83
Loading...
  • Open19.18
  • Day High19.18
  • Day Low18.20
  • Prev Close18.26
  • 52 Week High27.83
  • 52 Week High Date08/04/22
  • 52 Week Low7.74
  • 52 Week Low Date01/21/22

Key Stats

  • Market Cap456.447M
  • Shares Out24.45M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change58.35

KEY STATS

  • Open19.18
  • Day High19.18
  • Day Low18.20
  • Prev Close18.26
  • 52 Week High27.83
  • 52 Week High Date08/04/22
  • 52 Week Low7.74
  • 52 Week Low Date01/21/22
  • Market Cap456.447M
  • Shares Out24.45M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change58.35

RATIOS/PROFITABILITY

  • EPS (TTM)-1.85
  • P/E (TTM)-10.09
  • Fwd P/E (NTM)-8.66
  • EBITDA (TTM)-45.598M
  • ROE (TTM)-28.05%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/30/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aerovate Therapeutics Inc

 

Profile

MORE
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse...
Mark Iwicki
Independent Chairman of the Board
Timothy Noyes
Chief Executive Officer, Director
Benjamin Dake Ph.D.
President, Chief Operating Officer, Secretary
George Eldridge
Chief Financial Officer, Treasurer
Address
930 Winter Street, Suite M-500
Waltham, MA
02451
United States

Top Peers

SYMBOLLASTCHG%CHG
GLUE
Monte Rosa Therapeutics Inc
8.48-0.17-1.97%
CMPX
Compass Therapeutics Inc.
4.37-0.08-1.80%
PMVP
PMV Pharmaceuticals Inc
10.24+0.17+1.69%
VERA
Vera Therapeutics Inc
16.35-0.15-0.91%
ALXO
ALX Oncology Holdings Inc
10.68+0.06+0.56%